Solid dosage forms containing iguratimod
A solid preparation using polyvinyl alcohol and polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer as binders enhances iguratimod's dissolution, addressing solubility and agglomeration issues without mechanical pulverization, resulting in improved dissolution rates.
Patent Information
- Application Number
- JP2019146797
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2019-08-08
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2039-08-08
AI Technical Summary
Iguratimod, a poorly water-soluble drug, faces challenges in dissolution and agglomeration during handling, and existing methods like mechanical pulverization are not suitable for improving its solubility.
A solid preparation containing iguratimod is formulated with polyvinyl alcohol and polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer as binders, along with excipients and disintegrants like crystalline cellulose and carmellose calcium, to enhance dissolution without mechanical pulverization.
The formulation significantly improves the dissolution properties of iguratimod, achieving higher dissolution rates compared to conventional methods.
Smart Images

Figure 0007594353000002 
Figure 0007594353000001
Abstract
Description
[Technical field]
[0001] The present invention relates to a solid formulation having improved dissolution properties of iguratimod from the formulation. [Background technology]
[0002] Iguratimod (generic name) has the chemical name N-[7-[(methanesulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]formamide, and has the effect of suppressing the production of immunoglobulins by B cells and the production of inflammatory cytokines by monocytes / macrophages and synovial cells, and is used as an anti-rheumatic drug (Non-Patent Document 1, Non-Patent Document 2).
[0003] Regarding the solubility of iguratimod, it is described that it is "slightly soluble in acetonitrile, extremely slightly soluble in ethanol (99.5), and almost insoluble in water" (Non-Patent Document 1, Non-Patent Document 2), indicating that iguratimod is a drug that is poorly soluble in water.
[0004] It is known that solid preparations containing poorly water-soluble drugs can have poor dissolution, and the most common method to improve dissolution is to reduce the size of the drug by mechanical grinding. However, iguratimod is prone to electrostatic charging and aggregation, which poses problems in terms of handling.
[0005] Patent Document 1 discloses a formulation method that does not involve mechanical pulverization, in which 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (corresponding to iguratimod), crystalline cellulose, and a disintegrant are charged into a granulator to prepare a mixed powder, water is then added and mixed, and a binder solution is then added and granulated to improve dissolution. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] Patent No. 4608087 [Non-patent literature]
[0007] [Non-Patent Document 1] "Careram (registered trademark) Tablets" Pharmaceutical Interview Form Revised in January 2017 (Revised 6th Edition) [Non-Patent Document 2] "Corbet (registered trademark) Tablets" Pharmaceutical Interview Form Revised January 2018 (1st edition) Summary of the Invention [Problem to be solved by the invention]
[0008] An object of the present invention is to improve the dissolution properties of iguratimod in a solid preparation containing iguratimod without undergoing a special production process such as mechanical pulverization. [Means for solving the problem]
[0009] As a result of intensive research into solving the above problems, the present inventors have found that, when producing a solid formulation containing iguratimod as an active ingredient, the dissolution of the drug from the solid formulation can be improved by including at least one binder selected from the group consisting of polyvinyl alcohol and polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, and have thus completed the present invention.
[0010] That is, the present invention includes the following inventions. <1> A solid formulation comprising iguratimod and at least one binder selected from the group consisting of polyvinyl alcohol and polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer. <2> Further comprising an excipient, <2> 2. The solid formulation according to claim 1 . <3> Further, containing a disintegrant, <1> or <2> 2. The solid formulation according to claim 1 . <4> The excipient is crystalline cellulose; <2> or <3> 2. The solid formulation according to claim 1 . <5> The disintegrant is calcium carmellose. <3> or <4> 2. The solid formulation according to claim 1 . <6> The content of the binder is 0.1% by weight to 10% by weight based on the total weight of the solid preparation. <1> ~ <5> 2. The solid formulation according to claim 1 , <7> The content of the binder is 0.5% by weight to 5% by weight based on the total weight of the solid preparation. <1> ~ <5> 2. The solid formulation according to claim 1 , <8> It is a tablet, <1> ~ <7> 2. The solid formulation according to claim 1 , Effect of the Invention
[0011] According to the solid preparation of the present invention, the dissolution property of iguratimod, which is poorly soluble in water, can be improved. [Brief description of the drawings]
[0012] [Figure 1] FIG. 1 shows the results of a dissolution test using the Japanese Pharmacopoeia No. 2 fluid. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] The solid preparation of the present invention will be described in detail below.
[0014] Iguratimod can be easily produced according to methods disclosed in the art, suitable examples of which include the method disclosed in JP-A-2-49778.
[0015] Polyvinyl alcohol is usually produced by polymerizing vinyl acetate and then completely or partially saponifying it, so the polyvinyl alcohol of the present invention may include a completely or partially saponified product. The polyvinyl alcohol used in the present invention may be a commercially available product, such as Gohsenol (registered trademark) EG-05PW (manufactured by Mitsubishi Chemical).
[0016] The polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer used in the present invention may be a commercially available product, for example, POVACOAT (registered trademark, manufactured by Daido Chemical Industry Co., Ltd.).
[0017] The content of the binder in the solid preparation of the present invention can be 0.1% by weight to 10% by weight, 0.5% by weight to 5% by weight, or 1% by weight to 3% by weight, more preferably 2% by weight, and most preferably 1.9% by weight, based on the total weight of the solid preparation.
[0018] The solid preparation of the present invention may further contain at least one pharma- ceutically acceptable additive, if desired, such as a binder, disintegrant, excipient, lubricant, emulsifier, stabilizer, flavor, colorant, flavoring, diluent, etc.
[0019] Examples of binders that can be used in the present invention include methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, polyvinylpyrrolidone, gelatin, agar, starch syrup, beeswax, alginic acid, sodium alginate, pullulan, pectin, partially pregelatinized starch, dextrin, xanthan gum, gum arabic, guar gum, carboxyvinyl polymer, ammonioalkyl methacrylate copolymer, carboxyvinyl polymer, carboxymethylethyl cellulose, polyvinyl alcohol-polyethylene glycol graft copolymer, macrogol, methacrylic acid copolymer, etc. These binders may be used alone or in combination with one or more of at least one binder selected from the group consisting of polyvinyl alcohol and polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer.
[0020] Examples of excipients that can be used in the present invention include celluloses such as crystalline cellulose, ethyl cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, and hydroxypropyl methylcellulose (hypromellose, etc.); starches such as corn starch, potato starch, wheat starch, rice starch, partially pregelatinized starch, and hydroxypropyl starch; sugars such as glucose, lactose (including anhydrous lactose), white sugar (including refined white sugar), refined white sugar, powdered sugar, trehalose, dextran, and dextrin; mannitol, xylitol, and the like. Examples of suitable sugar alcohols include sugar alcohols such as maltitol, sorbitol, erythritol, maltitol, and powdered reduced maltose syrup; disaccharides such as sucrose, lactose, maltose, trehalose, and their substituted derivatives; and inorganic salts such as glycerin fatty acid esters, magnesium aluminometasilicate, synthetic hydrotalcite, anhydrous calcium phosphate, calcium triphosphate, calcium carbonate, precipitated calcium carbonate, calcium silicate, calcium hydrogen phosphate hydrate, calcium lactate, and sodium hydrogen carbonate. These may be used alone or in combination of two or more.
[0021] Examples of disintegrants that can be used in the present invention include crystalline cellulose, carboxymethylcellulose (carmellose), sodium carboxymethylcellulose, croscarmellose sodium, carboxymethylcellulose calcium, low-substituted hydroxypropylcellulose, crospovidone, sodium carboxymethylstarch, hydroxypropylstarch, starch, partially pregelatinized starch, sodium starch glycolate, calcium carbonate, precipitated calcium carbonate, calcium citrate, light anhydrous silicic acid, synthetic aluminum silicate, and the like. One or a mixture of two or more of these may be used.
[0022] Examples of lubricants that can be used in the present invention include stearic acid, sodium stearyl fumarate, magnesium stearate, calcium stearate, sucrose fatty acid esters, hardened oils, glycerin, glycerin fatty acid esters, carnauba wax, and talc. These may be used alone or in combination of two or more.
[0023] Examples of fluidizing agents that can be used in the present invention include light anhydrous silicic acid, hydrous silicon dioxide, magnesium aluminometasilicate, stearic acid, and talc, and one or more of these may be used in combination.
[0024] Examples of sweeteners that can be used in the present invention include aspartame, saccharin, stevia, amacha powder, sucralose, acesulfame potassium, white sugar, sorbitol, reduced maltose syrup, saccharin, licorice, and thaumatin, and one or more of these may be used in combination.
[0025] Examples of flavorings that can be used in the present invention include orange, vanilla, strawberry, yogurt, menthol, fennel oil, cinnamon oil, spruce oil, peppermint oil, and green tea powder, and one or more of these may be used in combination.
[0026] Examples of colorants that can be used in the present invention include ferric oxide, yellow ferric oxide, black ferric oxide, titanium oxide, talc, Food Yellow No. 4, Food Yellow No. 4 Aluminum Lake, Food Yellow No. 5, Food Red No. 2, Food Red No. 3, Food Red No. 102, Food Blue No. 1, methylene blue, carmine, and riboflavin, and one or more of these may be used in combination.
[0027] Examples of flavoring agents that can be used in the present invention include glutamic acid, fumaric acid, succinic acid, citric acid, sodium citrate, tartaric acid, malic acid, ascorbic acid, sodium chloride, and menthol, and one or more of these may be used in combination.
[0028] Examples of plasticizers that can be used in the present invention include triethyl citrate, glycerin, triacetin, castor oil, macrogol, propylene glycol, and glycerin monostearate, and one or more of these may be used in combination.
[0029] As the stabilizer that can be used in the present invention, stabilizers that are known per se in the field of pharmaceutical formulations can be used.
[0030] The solid formulation of the present invention may also be a combination tablet containing two or more active pharmaceutical ingredients. Examples of other types of active pharmaceutical ingredients that can be combined with iguratimod include, but are not limited to, other antirheumatic drugs, nonsteroidal anti-inflammatory drugs, immunosuppressants, and biological agents.
[0031] The solid preparation of the present invention may be, for example, a solid preparation suitable for oral administration such as a tablet, a granule, a fine granule, a capsule, or a pill, among which a tablet is preferred, and a single-layer tablet is more preferred. When the solid preparation of the present invention is a tablet, the shape of the tablet may be any of a round shape, an oval shape, an oblong shape, or the like. If necessary, the tablet may be coated with a coating agent. Furthermore, it may be possible to print marks, letters, or the like for improving identification, and a dividing line may be applied.
[0032] The solid preparation of the present invention can be produced by a general production method, for example, by the following production method. First, granules are obtained by producing a granulated material using iguratimod and at least one binder selected from the group consisting of polyvinyl alcohol and polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer. Granulation methods include known granulation methods used in pharmaceutical preparations, such as fluidized bed granulation and agitation granulation. The granules obtained may be mixed with a disintegrant and a lubricant, and then compressed and molded into tablets using a tablet press. The tablets obtained may be film-coated using a ventilated pan coating device or the like. Capsules may also be prepared by encapsulating iguratimod and additives in powder form or as granules. EXAMPLES
[0033] The present invention will be described in more detail below with reference to the following Test Examples and Examples, but the present invention is not limited thereto.
[0034] Example 1 25.0 parts by weight of iguratimod, 86.0 parts by weight of crystalline cellulose (manufactured by Asahi Kasei, PH-101), and 9.0 parts by weight of carmellose calcium (manufactured by Gotoku Pharmaceutical, ECG-505) were weighed out and mixed in an agate mortar to obtain a mixed powder. Separately, 1.9 parts by weight of polyvinyl alcohol (Mitsubishi Chemical, Gohsenol EG-05PW) was added to and dissolved in 51 parts by weight of purified water to obtain a binding solution. The above-mentioned binding liquid was added to the mixed powder, and the mixture was wet-granulated using an agate mortar. 25 parts by weight of purified water was further added, and the mixture was wet-granulated using an agate mortar to obtain a granulated powder. The obtained granulated powder was dried and sized through a No. 24 sieve to obtain a sized powder. To the obtained sized powder, 56.3 parts by weight of crystalline cellulose (UF-702, manufactured by Asahi Kasei) and 5.0 parts by weight of carmellose calcium were added and mixed, and then 1.8 parts by weight of magnesium stearate (manufactured by Taihei Chemical Industry) was added and mixed to obtain a tablet powder. The obtained tablet powder was compressed into tablets with a diameter of 7.5 mm and a mass of 185 mg using a single punch tableting machine (simple tablet forming machine HNDTAB-200 type, manufactured by Ichihashi Seiki Co., Ltd.) to obtain tablets containing iguratimod.
[0035] Example 2 Tablets containing iguratimod were obtained by the same method as in Example 1 above, except that, in place of the polyvinyl alcohol in Example 1, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer (POVACOAT, manufactured by Daido Chemical Industry Co., Ltd.) was used as the binder in the formulation shown in Table 1 below.
[0036] Comparative Example 1 Tablets containing iguratimod were obtained using the same method as in Example 1 above, except that, with the formulation shown in Table 1 below, hydroxypropyl cellulose (HPC-L, manufactured by Nippon Soda Co., Ltd.) was used as the binder instead of polyvinyl alcohol in Example 1.
[0037] Comparative Example 2 Tablets containing iguratimod were obtained by the same manufacturing method as in Example 1 above, except that, with the formulation in Table 1 below, hypromellose (TC-5R, manufactured by Shin-Etsu Chemical Co., Ltd.) was used as the binder instead of the polyvinyl alcohol in Example 1.
[0038] Comparative Example 3 Tablets containing iguratimod were obtained using the same method as in Example 1 above, except that, in the formulation of Table 1 below, methylcellulose (Metolose SM-4, manufactured by Shin-Etsu Chemical Co., Ltd.) was used as the binder instead of polyvinyl alcohol in Example 1.
[0039] [Table 1]
[0040] Test Example 1 Dissolution Test For the tablets produced in Examples 1 and 2 and Comparative Examples 1 to 3, the dissolution rates of iguratimod were measured as follows. The test fluid used was 900 mL of the second dissolution test fluid described in the Japanese Pharmacopoeia, 17th Edition, and the test was performed using the paddle method at 50 revolutions per minute. 20 mL of the dissolution fluid was collected 5, 10, 15, 30, 60, 120, and 360 minutes after the start of the dissolution test, and 20 mL of the test fluid was immediately added. The collected dissolution fluid was filtered through a filter with a pore size of 0.45 μm to prepare the sample. The amount of iguratimod contained in the obtained sample was measured by liquid chromatography under the following conditions, and the dissolution rates were calculated. The results are shown in Figure 1.
[0041] Test conditions Detector: Ultraviolet absorption photometer (measurement wavelength: 257 nm) Column: A stainless steel tube having an inner diameter of 4.6 mm and a length of 15 cm is packed with 5 μm octadecylsilylated silica gel for liquid chromatography. Column temperature: constant temperature around 40℃ Mobile phase: 0.04 mol / L ammonium dihydrogen phosphate solution: acetonitrile mixture = 3:2
[0042] As shown in FIG. 1, the iguratimod-containing tablets of the present invention, which used polyvinyl alcohol or polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer as a binder, showed a high dissolution rate. In particular, in a system in which the tablet of Comparative Example 1, which mimics the formulation (composition) of Patent Document 1, exhibited a superior dissolution rate compared to Comparative Examples 2 and 3, it was shown that the tablet of the present invention has an even further improved dissolution rate. [Industrial Applicability]
[0043] According to the present invention, it is possible to provide a solid preparation containing poorly water-soluble iguratimod as an active ingredient and having improved dissolution properties.
Claims
1. A solid preparation comprising iguratimod and a granule containing at least one binder selected from the group consisting of polyvinyl alcohol, which is a partially saponified product, and polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, which is a partially saponified product of polyvinyl alcohol (however, the granule excludes granules having an average particle size of less than 3 μm).
2. The solid formulation according to claim 1 , further comprising an excipient.
3. The solid formulation according to claim 1 or 2, further comprising a disintegrant.
4. The solid formulation according to claim 2 or 3, wherein the excipient is crystalline cellulose.
5. The solid formulation according to claim 3 or 4, wherein the disintegrant is calcium carmellose.
6. The solid formulation according to any one of claims 1 to 5, wherein the content of the binder is 0.1% by weight to 10% by weight based on the total weight of the solid formulation.
7. The solid formulation according to any one of claims 1 to 5, wherein the content of the binder is 0.5% by weight to 5% by weight based on the total weight of the solid formulation.
8. The solid formulation according to any one of claims 1 to 7, which is a tablet.
9. A granule is produced by wet granulation using iguratimod and at least one binder selected from the group consisting of polyvinyl alcohol, which is a partially saponified product, and polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, which is a partially saponified product of polyvinyl alcohol; The granules are mixed with additives and then compressed and molded. A method for producing a solid dosage form.
Citation Information
Patent Citations
Preparation method of iguratimod nano-drug particle
CN109512786A
Method of preparing solid formulation
JP2001240540A
Irbesartan-containing pharmaceutical composition with good elution property and orally disintegrable tablet
JP2010053047A
Method for producing physiologically active substance-containing granule
JP2013023463A
Granulated material and oral pharmaceutical preparation containing the same as well as production method of granulated material and oral pharmaceutical preparation
JP2017081850A
